Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dynavax secures $3 million flu vaccine grant
The National Institutes of Health (NIH), has been funding Dynavax’s research since 2003, which focuses on a new vaccine that incorporates a second- generation TLR9 agonist and the
The National Institutes of Health (NIH), has been funding Dynavax’s research since 2003, which focuses on a new vaccine that incorporates a second- generation TLR9 agonist and the
Viracept was recalled in June and has now had its license put on hold. The European Medicines Agency (EMEA), which handles drug safety, recommended the Commission suspend Roche’s
With the exception of these countries (Denmark, Finland, Iceland, Norway and Sweden), Wyeth markets BeneFIX around the world. Under the terms of the agreement, Biovitrum will receive a
The drug, PRX-08066, is a novel 5-HT2B antagonist that the company believes represents a new mechanism of action for treating pulmonary hypertension (PH). Epix said that PRX-08066 resulted
Sales of cancer drug Nexavar jumped 161% to E60 million, which has contributed to Bayer’s healthcare division accounting for roughly 44% of group sales and half of underlying
AVI BioPharma also said that it would be optimizing compounds targeting infectious diseases, and testing new technologies that leverage the Neugene antisense platform, such as exon-skipping pre-RNA interference
This announcement marks the third collaboration between AstraZeneca and BioFocus DPI. In August 2006, Galapagos announced BioFocus DPI’s first drug discovery collaboration with AstraZeneca. Under a second program
GammaCan anticipates filing an IND with the FDA for a Phase I/II clinical trial by year-end, and initiating clinical testing of VitiGam in early 2008. Orphan drug designation
The world’s largest drug company said it currently has 47 drugs in the Phase II stage, 38 in Phase I, and 11 in Phase III. Four drugs at
KineMed’s proprietary reverse cholesterol transport (RCT) technology will be used to evaluate investigational compounds discovered by Merck, the company said. RCT is the only known metabolic pathway by